In the last trading session, the stock price of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) declined more than 1% to close the day at $71.73. More recently, the firm reported that it has achieved its registration target of 16 subjects in its Phase II FAB-C clinical study assessing ZYN002 Cannabidiol gel in children with FXS. ZYN002 CBD gel marks as the first and single patent-protected, synthetic Cannabinoid that is made as a permeation-enhanced gel targeting transdermal delivery. It was awarded orphan drug status by the U.S. FDA for the treatment for FXS.
Utilizing proprietary sublingual spray know-how and capabilities to advance pharmaceutical CBDs, Insys Therapeutics Inc (NASDAQ:INSY) is advancing a pipeline of products planned to resolve the clinical shortcomings of current commercial products. Last year in May, the company reported that the U.S. FDA has permitted the final product label for ‘Syndros™’ oral solution, CII, which is a liquid formulation of